Oncology and Hematology News and Journal Articles
In this interview, we discuss symptom self-management strategies reported by adolescents and young adults with cancer, including some of the most common symptoms affecting this patient population and effective self-management techniques.
Afatinib resulted in improved progression-free survival compared with gefitinib in treatment-naive non–small-cell lung cancer patients with EGFR mutations.
Cancer patients have an increased risk of several common mental disorders, including depression and anxiety, beginning almost a year prior to the diagnosis.
First-line osimertinib, a targeted therapy against EGFR mutations, was found to be effective in patients with advanced non–small-cell lung cancer, resulting in a 77% overall response rate.
Adding ixazomib to the combination of lenalidomide/dexamethasone resulted in a more than 35% improvement in the risk for disease progression or death in patients with relapsed or refractory multiple myeloma.
In this video, Dr. Paz-Ares discusses a phase III study that showed that nivolumab improved survival and response rates in previously treated patients with metastatic non-squamous non-small-cell lung cancer (NSCLC).
In this video, Steven I. Sherman, MD, discusses the final overall survival analysis of the EXAM study, a randomized, placebo-controlled phase III trial of cabozantinib in medullary thyroid carcinoma patients.
In this video, Dr. El-Khoueiry discusses results from a phase I/II study that suggest the PD-1 inhibitor nivolumab is safe and effective in advanced hepatocellular carcinoma.
In this video, Dr. Tap discusses a randomized phase Ib/II trial that found that adding olaratumab to doxorubicin dramatically improved survival in patients with advanced soft-tissue sarcoma.
The journal ONCOLOGY includes a cartoon at the end of each issue. Here are the collected cartoons to date.